Lyell Immunopharma Inc. has set terms of its initial public offering, which would value the California-based T cell reprogramming company at up to $4.37 billion. The company is looking to raise up to $450 million, as it is offering 25.0 million shares in the IPO, which is expected to price between $16 and $18 a share. The company expects to have 242.83 million shares outstanding after the IPO. The stock is expected to list on the Nasdaq under the ticker symbol "LYEL." Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley are the lead underwriters.
In this article
No tags related to this article.